医薬品リファレンス
Cosibelimab
Cosibelimab is a medicine in the class oncology. It is used for squamous cell carcinoma.
- 薬効分類: Oncology
- 効能・効果: squamous cell carcinoma
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- 一般的な剤形
- 注射剤
- 一般的な規格
- 300 mg/5 ml
- 既知の相互作用
- 3 (中等度: 2 · 軽度: 1)
- 商品名
- 1
- 国・市場
- 1
何に使われるか
作用のしくみ
Cosibelimab-ipdl binds PD-L1 and blocks its interaction with PD-1 and B7.1 receptors, releasing the inhibitory effect of PD-L1 on the anti-tumor immune response. It also induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.
成人の通常用量（添付文書の要約）
Metastatic or locally advanced cutaneous squamous cell carcinoma not amenable to curative surgery or radiation: 1,200 mg IV infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm: PD-L1 blockade can disrupt immune tolerance to the fetus, and the antibody can cross the placenta. Check pregnancy status; use effective contraception during treatment and for 4 months after the last dose.
- 授乳
- Unsafe No data on milk levels. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 4 months after the last dose.
報告されている副作用
- Fatigue
- Musculoskeletal pain
- Rash
- Diarrhea
- Hypothyroidism
- Constipation
禁忌
- None.
注意が必要な方
- Severe and fatal immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic reactions, nephritis, transplant rejection) can occur in any organ; monitor liver enzymes, creatinine and thyroid function at baseline and periodically.
- Infusion-related reactions: interrupt, slow the infusion, or permanently discontinue based on severity.
- Fatal and other serious complications can occur with allogeneic HSCT before or after PD-1/PD-L1 blocking antibody.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (3)
- Cosibelimab + Piperacillin Moderate
- Cosibelimab + Piperacillin-tazobactam Moderate
- Cosibelimab + Penicillin g Minor
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Cosibelimabの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Cosibelimab used for?
Cosibelimab is a medicine in the class oncology. It is used for Squamous cell carcinoma.
What side effects have been reported with Cosibelimab?
Fatigue, Musculoskeletal pain, Rash, Diarrhea, Hypothyroidism, Constipation.
Can Cosibelimab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: PD-L1 blockade can disrupt immune tolerance to the fetus, and the antibody can cross the placenta. Check pregnancy status; use effective contraception during treatment and for 4 months after the last dose. Breastfeeding: Unsafe. No data on milk levels. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 4 months after the last dose.
What does Cosibelimab interact with?
MediHelp lists 3 known interactions for Cosibelimab. Moderate: 2 · Minor: 1. The most serious include Piperacillin, Piperacillin-tazobactam, Penicillin g.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
